Sydney Jennings

Benjamin Ungar, MD, discusses his presentation at AAD 2025 covering advances and updates about rosacea and seborrheic dermatitis.

AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.

AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

AAD 2025. New research indicates that dual inhibition of IL-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.

Preview the posters and abstracts covering atopic dermatitis advances from Arcutis, Incyte, Lilly and Sanofi/Regeneron.

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.

AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.

Your daily dose of the clinical news you may have missed.

The impact of food elimination diets on medication previously was unknown, according to new research presented at AAAAI 2025.

Your daily dose of the clinical news you may have missed.

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing, according to GSK.

Your daily dose of the clinical news you may have missed.

The Loss of Pulse Detection feature will begin rolling out in the US late next month.

The company announced completion of target enrollment in the REZOLVE-AA study of rezpegaldesleukin in people with severe-to-very-severe alopecia areata.

Your daily dose of the clinical news you may have missed.

Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.

The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

AAAAI 2025: Phase 2 study results showed POIT with home-measured peanut products was not only highly effective but also posed few risks.

Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.

Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.

Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.

Neal Bhatia, MD, highlighted updates in the management of actinic keratosis, emphasizing strategies to reduce skin cancer risk and improve patient outcomes.

Cheri Frey, MD, explored novel active ingredients, advancements in skin care formulations at the Midwinter Clinical Derm Conference.

Theodore Rosen, MD, underscored the critical need for responsible antibiotic use in dermatology to combat the accelerating crisis of drug-resistant infections.

Insights into managing molluscum contagiosum, HPV-related warts, and other infections took center stage at the Midwinter Clinical Hawaii Derm Conference.

From new biologics for AD to JAK inhibitors for children with alopecia areata, get the latest updates in pediatric dermatology, here.

From black tea compresses to effective mind-body interventions for symptom control, Peter Lio, MD, shares 4 pearls for effective AD management.

Insights include new data on combination therapies, topical antiandrogens, and innovative retinoid formulations.